Answer
The most frequently reported adverse effects of ofatumumab (Kesimpta) are upper respiratory tract infections (39.4%), systemic injection-related reactions (20.6%), urinary tract infections (11.9%) and injection-site reactions (10.9%).
Sources for this answer
- Kesimpta 20 mg solution for injection in pre-filled penNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.8 Undesirable effects · Version 7Document updated
Sources checked